Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;11(2):237-41.
doi: 10.1016/j.clml.2011.03.005. Epub 2011 Apr 8.

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

Ali Al Ameri  1 , Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Jianqin Shan, Sherry Pierce, Jorge Cortes, Hagop Kantarjian
Affiliations

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

Ali Al Ameri et al. Clin Lymphoma Myeloma Leuk. 2011 Apr.

Abstract

Purpose: To analyze the incidence and significance of thrombocytopenia in patients with myelodysplastic syndrome (MDS).

Patients and methods: A total of 2517 patients with MDS referred to our institution since 1993 were analyzed, with a specific focus on the incidence and associations of thrombocytopenia.

Results: The median age of the study group was 66 years. The median survival was 13 months. Platelet counts <100 × 10(9)/L were noted in 65%, and platelets counts <30 × 10(9)/L in 26%. Each platelets count drop below the range of 200 × 10(9)/L has shown a larger magnitude change in terms of worsening effect on survival. Therefore, smaller ranges of platelet counts of <200 × 10(9)/L were studied. Platelet cutoffs of 30, 50, and 200 × 10(9)/L thus were identified to have significant associations with differences in survival. Significant thrombocytopenia was associated with poor performance, other cytopenias, adverse karyotype, and advanced MDS phases. Thrombocytopenia was associated with worse prognosis; it also was predicted for worse outcome within each of the International Prognostic Scoring System risk groups.

Conclusion: Prognosis in MDS is directly associated with the severity of thrombocytopenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival of the Study Group
Figure 2
Figure 2
Survival by Platelet Counts
Figure 3
Figure 3
Figure 3A Survival by Platelet Counts within International Prognostic Scoring System (IPSS)-low Figure 3B Survival by Platelet Counts Within IPSS-intermediate-1 Figure 3C Survival by Platelet Counts Within IPSS-intermediate-2 Figure 3D Survival by Platelet Counts Within IPSS-high
Figure 3
Figure 3
Figure 3A Survival by Platelet Counts within International Prognostic Scoring System (IPSS)-low Figure 3B Survival by Platelet Counts Within IPSS-intermediate-1 Figure 3C Survival by Platelet Counts Within IPSS-intermediate-2 Figure 3D Survival by Platelet Counts Within IPSS-high
Figure 3
Figure 3
Figure 3A Survival by Platelet Counts within International Prognostic Scoring System (IPSS)-low Figure 3B Survival by Platelet Counts Within IPSS-intermediate-1 Figure 3C Survival by Platelet Counts Within IPSS-intermediate-2 Figure 3D Survival by Platelet Counts Within IPSS-high
Figure 3
Figure 3
Figure 3A Survival by Platelet Counts within International Prognostic Scoring System (IPSS)-low Figure 3B Survival by Platelet Counts Within IPSS-intermediate-1 Figure 3C Survival by Platelet Counts Within IPSS-intermediate-2 Figure 3D Survival by Platelet Counts Within IPSS-high
See this image and copyright information in PMC

References

    1. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood. 2002;99:3074–5. - PubMed
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. - PubMed
    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88. - PubMed
    1. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–61. - PMC - PubMed
    1. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–4. - PubMed